•
Global healthcare leader Sanofi (NASDAQ: SNY) and China-based Corxel Pharmaceuticals (CORXEL), formerly known as Ji Xing Pharmaceuticals, have jointly announced an official agreement. Under this partnership, Sanofi is set to acquire exclusive development and commercialization rights to CORXEL’s aficamten in Greater China. The financial details of the deal have not…
•
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced a significant licensing agreement with compatriot firm Corxel Pharmaceuticals (CORXEL), formerly known as Ji Xing Pharmaceuticals. The agreement grants Grand Pharma exclusive development and commercialization rights to CORXEL’s OC-01 (varenicline) nasal spray and OC-02 (simpinicline) nasal spray in Greater China,…
•
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced a strategic partnership with CORXEL, formerly known as Ji Xing Pharmaceuticals. The financial details of the agreement have not been disclosed, but it is confirmed that Apeloa will provide professional CDMO services to CORXEL on…
•
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has received approval from China’s National Medical Products Administration (NMPA) for its varenicline nasal spray, which is indicated for increasing tear secretion in patients diagnosed with xerophthalmia. Clinical Studies Support NMPA ApprovalThe NMPA’s approval was grounded in data…
•
CORXEL, formerly known as Ji Xing Pharmaceuticals and Cytokinetics Inc (CYTK, NASDAQ: CYTK) have achieved a significant milestone with the acceptance of their market filing for aficamten by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. Aficamten, a next-generation cardiac myosin inhibitor, is…
•
The Center for Drug Evaluation (CDE) has indicated on its website that five investigational drugs and one companion diagnostic (CDx) are on track to receive priority review status. The drugs include: Novartis’ Fabhalta (iptacopan) for C3 glomerulopathy (C3G), a best-in-class specific complement factor B oral inhibitor that comprehensively controls intravascular…
•
CORXEL, formerly known as Ji Xing Pharmaceuticals, a China-based pharmaceutical company, has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct the Phase III ACACIA-HCM study for its drug aficamten (CK-3773274) in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) in China. Aficamten, a next-generation cardiac myosin…
•
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has secured a licensing agreement with Biogen (NASDAQ: BIIB) for the global clinical development rights to the US company’s pipeline candidate BIIB131. The terms of the deal include an undisclosed upfront payment, milestone payments, and royalties on future…
•
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a strategic partnership with WuXi STA, a subsidiary of WuXi AppTec (HKG: 2359, SHA: 603259), to establish a sterile nasal spray production line. This collaboration aims to leverage the strengths of both companies, with the new…
•
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct Phase III clinical trials for its LNZ100 (aceclidine) and LNZ101 (aceclidine/brimonidine) in presbyopia. Exclusive Rights and Licensing Deal with LENZ TherapeuticsJi Xing…
•
Shanghai-based Ji Xing Pharmaceuticals, a company backed by RTW Investments, has announced a strategic collaboration agreement with Taiwan-headquartered TSH Biopharm (TSH). Under this agreement, TSH will provide commercialization support for varenicline solution nasal spray (US brand name Tyrvaya) in Taiwan. The financial details of the collaboration were not disclosed. Varenicline…
•
Shanghai-based Corxel Pharmaceuticals (CORXEL), supported by RTW Investments, has announced that its OC-01 (varenicline) nasal spray has been approved by the Hainan Medical Products Administration as a clinically urgently needed import drug in Bo’ao Super Hospital. This marks a significant milestone as the product is the world’s first and only…
•
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global rights to US firm PhaseBio Pharmaceuticals Inc.’s pre-clinical drug candidate PB6440. This strategic partnership aims to advance the development of a next-generation aldosterone synthetase inhibitor (ASi) with significant potential in treating cardiovascular, renal, and metabolic…
•
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that a market filing for its investigational omecamtiv mecarbil has been accepted for review by the Center for Drug Evaluation (CDE). The small molecule is a potential first-in-class cardiac myosin activator being developed as a treatment for heart failure with reduced…
•
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that the first patient has been enrolled in a Phase III clinical study for its OC-01 (varenicline) nasal spray in China. The study aims to evaluate the efficacy and safety of OC-01 in treating dry eye and neurotrophic keratopathy. Drug ProfileOC-01…
•
China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III clinical study in China for etripamil, a drug candidate being assessed as a treatment for paroxysmal supraventricular tachycardia (PSVT). The multi-center, randomized, double-blind, placebo-controlled Phase III study will evaluate the efficacy and safety of self-administered…
•
China-based Ji Xing Pharmaceuticals announced receiving approval from the Center for Drug Evaluation (CDE) to initiate a Phase III clinical study for its aficamten (CK-3773274) in symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This study is part of the global multi-center SEQUOIA-HCM trial. Drug Profile and MechanismAficamten is a next-generation cardiac myosin…